Vosoritide acetate BMN 111 acetate|西域试剂

Vosoritide acetate BMN 111 acetate,99.40%

产品编号：Bellancom-P3503A| 分子式：C₁₇₆H₂₉₀N₅₆O₅₁S₃.C₂H₄O₂| 分子量：4162.78

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P3503A	￥1600.00	杭州北京（现货）
Bellancom-P3503A	￥4000.00	杭州北京（现货）
Bellancom-P3503A	￥6400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Vosoritide acetate BMN 111 acetate

产品介绍

Vosoritide (BMN 111) acetate 是一种利尿钠肽受体 2 (NPR2) 激动剂，可作用于软骨细胞的增殖和分化，促进骨骼生长。

生物活性

Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that acts on the proliferation and differentiation of chondrocytes to promote bone growth.

体外研究

Vosoritide（0.1 μM；1 小时）acetate 降低软骨细胞中的 NPR2 磷酸化。
Vosoritide（0.1 μM；6 天）acetate 改善软骨细胞分化并增加培养的 Fgfr3^Y367C/+ 股骨的增殖生长板面积。
Vosoritide（10 μM；过夜）acetate 降低 ACH 生长板软骨细胞中的 ERK1/2 激活。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Chondrocyte cultures
Concentration:	0.1 μM
Incubation Time:	1 hour
Result:	Led to reduction in NPR2 phosphorylation.

Western Blot Analysis

Cell Line:	Chondrocyte
Concentration:	10 μM
Incubation Time:	Overnight
Result:	Prevented FGF-mediated increase in ERK1/2 phosphorylation.

体内研究
(In Vivo)

Vosoritide（皮下注射；800 μg/kg；每日一次；20 天）acetate 治疗可改善 Fgfr3 功能获得性突变小鼠的骨骼参数。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fgfr3^Y367C/+ mice
Dosage:	800 μg/kg
Administration:	Subcutaneous injection; 800 μg/kg; once daily; 20 days
Result:	Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.

体内研究

Vosoritide（皮下注射；800 μg/kg；每日一次；20 天）acetate 治疗可改善 Fgfr3 功能获得性突变小鼠的骨骼参数。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fgfr3^Y367C/+ mice
Dosage:	800 μg/kg
Administration:	Subcutaneous injection; 800 μg/kg; once daily; 20 days
Result:	Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.

体内研究

Vosoritide（皮下注射；800 μg/kg；每日一次；20 天）acetate 治疗可改善 Fgfr3 功能获得性突变小鼠的骨骼参数。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fgfr3^Y367C/+ mice
Dosage:	800 μg/kg
Administration:	Subcutaneous injection; 800 μg/kg; once daily; 20 days
Result:	Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 100 mg/mL (24.02 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.2402 mL	1.2011 mL	2.4022 mL
5 mM	0.0480 mL	0.2402 mL	0.4804 mL
10 mM	0.0240 mL	0.1201 mL	0.2402 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen